Final Activity Report Summary - LUNGCAABS (Utility of tumor antigens as therapeutic and diagnostic tools)
The project aimed the characterisation of naturally occurring immune responses against tumours elicited by the host (patient). We successfully showed that an immune response against the tumour-associated protein SOX2, associates with longer survival in patients with small cell lung cancer. Most importantly, we showed that this response is an independent prognostic criteria indicating that regardless of the patient's clinical state, the presence of antibodies is a marker for longer survival. These results have important implications for immunotherapy for small cell lung cancer patients.